Rheumatic immune-related adverse events from cancer immunotherapy

Leonard H. Calabrese, Cassandra Calabrese, Laura Cappelli

Research output: Contribution to journalReview article

Abstract

Immunotherapy has revolutionized the treatment of cancer, but a rapid rise in the use of the family of therapeutic agents known as checkpoint inhibitors (CPIs) is associated with a new group of immune-related adverse events (irAEs) in almost any organ system. Among these irAEs, rheumatic complications are common and seem to have features that are distinct from irAEs in other organ systems, including a highly variable time of clinical onset and the capacity to persist, possibly indefinitely, even after cessation of CPI therapy. In this Review, mechanisms of action of CPIs and how they might cause rheumatic irAEs are described. Also covered are epidemiology and clinical descriptions of rheumatic irAEs, plus guiding principles for managing irAEs. Finally, we outline future directions that must be taken in response to a series of unanswered questions and unmet needs that now confront rheumatologists who are, or will be, engaged in this new area of rheumatology.

Original languageEnglish (US)
Pages (from-to)569-579
Number of pages11
JournalNature Reviews Rheumatology
Volume14
Issue number10
DOIs
StatePublished - Oct 1 2018

Fingerprint

Immunotherapy
Rheumatology
Therapeutic Uses
Neoplasms
Epidemiology
Therapeutics
Direction compound
Rheumatologists

ASJC Scopus subject areas

  • Rheumatology

Cite this

Rheumatic immune-related adverse events from cancer immunotherapy. / Calabrese, Leonard H.; Calabrese, Cassandra; Cappelli, Laura.

In: Nature Reviews Rheumatology, Vol. 14, No. 10, 01.10.2018, p. 569-579.

Research output: Contribution to journalReview article

Calabrese, Leonard H. ; Calabrese, Cassandra ; Cappelli, Laura. / Rheumatic immune-related adverse events from cancer immunotherapy. In: Nature Reviews Rheumatology. 2018 ; Vol. 14, No. 10. pp. 569-579.
@article{8c7f18947fe54d6a88925b2b10eeb0db,
title = "Rheumatic immune-related adverse events from cancer immunotherapy",
abstract = "Immunotherapy has revolutionized the treatment of cancer, but a rapid rise in the use of the family of therapeutic agents known as checkpoint inhibitors (CPIs) is associated with a new group of immune-related adverse events (irAEs) in almost any organ system. Among these irAEs, rheumatic complications are common and seem to have features that are distinct from irAEs in other organ systems, including a highly variable time of clinical onset and the capacity to persist, possibly indefinitely, even after cessation of CPI therapy. In this Review, mechanisms of action of CPIs and how they might cause rheumatic irAEs are described. Also covered are epidemiology and clinical descriptions of rheumatic irAEs, plus guiding principles for managing irAEs. Finally, we outline future directions that must be taken in response to a series of unanswered questions and unmet needs that now confront rheumatologists who are, or will be, engaged in this new area of rheumatology.",
author = "Calabrese, {Leonard H.} and Cassandra Calabrese and Laura Cappelli",
year = "2018",
month = "10",
day = "1",
doi = "10.1038/s41584-018-0074-9",
language = "English (US)",
volume = "14",
pages = "569--579",
journal = "Nature reviews. Rheumatology",
issn = "1759-4790",
publisher = "Nature Publishing Group",
number = "10",

}

TY - JOUR

T1 - Rheumatic immune-related adverse events from cancer immunotherapy

AU - Calabrese, Leonard H.

AU - Calabrese, Cassandra

AU - Cappelli, Laura

PY - 2018/10/1

Y1 - 2018/10/1

N2 - Immunotherapy has revolutionized the treatment of cancer, but a rapid rise in the use of the family of therapeutic agents known as checkpoint inhibitors (CPIs) is associated with a new group of immune-related adverse events (irAEs) in almost any organ system. Among these irAEs, rheumatic complications are common and seem to have features that are distinct from irAEs in other organ systems, including a highly variable time of clinical onset and the capacity to persist, possibly indefinitely, even after cessation of CPI therapy. In this Review, mechanisms of action of CPIs and how they might cause rheumatic irAEs are described. Also covered are epidemiology and clinical descriptions of rheumatic irAEs, plus guiding principles for managing irAEs. Finally, we outline future directions that must be taken in response to a series of unanswered questions and unmet needs that now confront rheumatologists who are, or will be, engaged in this new area of rheumatology.

AB - Immunotherapy has revolutionized the treatment of cancer, but a rapid rise in the use of the family of therapeutic agents known as checkpoint inhibitors (CPIs) is associated with a new group of immune-related adverse events (irAEs) in almost any organ system. Among these irAEs, rheumatic complications are common and seem to have features that are distinct from irAEs in other organ systems, including a highly variable time of clinical onset and the capacity to persist, possibly indefinitely, even after cessation of CPI therapy. In this Review, mechanisms of action of CPIs and how they might cause rheumatic irAEs are described. Also covered are epidemiology and clinical descriptions of rheumatic irAEs, plus guiding principles for managing irAEs. Finally, we outline future directions that must be taken in response to a series of unanswered questions and unmet needs that now confront rheumatologists who are, or will be, engaged in this new area of rheumatology.

UR - http://www.scopus.com/inward/record.url?scp=85053302057&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=85053302057&partnerID=8YFLogxK

U2 - 10.1038/s41584-018-0074-9

DO - 10.1038/s41584-018-0074-9

M3 - Review article

C2 - 30171203

AN - SCOPUS:85053302057

VL - 14

SP - 569

EP - 579

JO - Nature reviews. Rheumatology

JF - Nature reviews. Rheumatology

SN - 1759-4790

IS - 10

ER -